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Pffect of Clopidogrel With and Without
ptifibatide on Tumor Necrosis Factor-Alpha
nd C-Reactive Protein Release After Elective Stenting
esults From the CLEAR PLATELETS 1b Study
aul A. Gurbel, MD, FACC, Kevin P. Bliden, BS, Udaya S. Tantry, PHD
altimore, Maryland
OBJECTIVES This study was performed to compare the effects of antiplatelet regimens on early inflammation
and cardiac marker release after elective stenting.
BACKGROUND Few data exist regarding the comparative effects of specific antiplatelet regimens on early
inflammation marker release after stenting.
METHODS In a 2  2 factorial randomized investigation, patients undergoing stenting were treated with
either clopidogrel alone (300 mg or 600 mg; n 60) or clopidogrel with eptifibatide (n 60).
Platelet aggregation (5 and 20 M adenosine diphosphate [ADP]), ADP-stimulated
expression of active glycoprotein (GP) IIb/IIIa, and platelet-bound P-selectin, tumor necrosis
factor (TNF)-, C-reactive protein (CRP), and cardiac markers were measured.
RESULTS Compared with a strategy of clopidogrel alone, clopidogrel  eptifibatide reduced the release
of cardiac markers. A marked reduction in platelet aggregation and active GP IIb/IIIa
expression (p 0.001) with clopidogrel eptifibatide was associated with a decrease in CRP
and TNF- release (p  0.001).
CONCLUSIONS A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of
inflammation and cardiac marker release, which was accompanied by superior platelet
inhibition immediately after percutaneous coronary intervention compared with a strategy of
clopidogrel alone. The mechanistic and clinical implications of attenuated periprocedural
inflammation and myocardial necrosis with a strategy of GP IIb/IIIa inhibition warrant
further investigation. (J Am Coll Cardiol 2006;48:2186–91) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084College of Cardiology Foundation
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fhrombosis and inflammation are important processes in-
uencing the development of ischemic events after percu-
aneous coronary intervention (PCI) (1). Recent clinical
rials established the effectiveness of glycoprotein (GP)
Ib/IIIa inhibitors with clopidogrel and aspirin in reducing
hrombotic events after PCI (2,3). However, controversy
emains regarding the optimal antiplatelet strategy for
lective stenting. In the CLEAR PLATELETS (Clopi-
ogrel Loading With Eptifibatide to Arrest the Reactivity
f Platelets) study, we demonstrated that a loading dose of
lopidogrel with a GP IIb/IIIa blocker was associated with
verall superior early platelet inhibition and decreased re-
ease of cardiac markers after PCI compared with clopi-
ogrel loading alone (4). In the CLEAR PLATELETS
tudy the effects of both high and standard clopidogrel
oading doses were investigated.
The role of platelet activation in modulating inflamma-
ion and the potential anti-inflammatory effects of clopi-
ogrel and GP IIb/IIIa inhibitors have been suggested in
ecent studies (5–9). However, the comparative anti-
nflammatory effects of clopidogrel with and without GP
Ib/IIIa blockade during stenting are not known. The
From the Sinai Center for Thrombosis Research, Baltimore, Maryland. This study
as supported by a grant from Millennium Pharmaceuticals, Inc., Cambridge,
assachusetts.m
Manuscript received October 20, 2005; revised manuscript received December 14,
005, accepted December 19, 2005.rimary goal of the present investigation (CLEAR
LATELETS 1b) was to compare the effects of the antiplate-
et regimens employed in the CLEAR PLATELETS study
n early inflammation marker release after PCI.
ETHODS
he CLEAR PLATELETS 1b study enrolled consecutive
lective stent patients and was an extension of the CLEAR
LATELETS study. Midway through the CLEAR
LATELETS study we initiated measurements of inflam-
ation markers in addition to platelet function analyses.
he CLEAR PLATELETS 1b study enrolled 60 addi-
ional patients for a total of 120 patients in whom analyses
f platelet function, cardiac markers, and inflammation
arkers were completed. The study extension was approved
y our investigational review board. The randomization
cheme in CLEAR PLATELETS 1b study was identical to
he CLEAR PLATELETS study. The exclusion and
nclusion criteria were previously described (4).
In a 2  2 factorial manner, patients were randomly
ssigned to one of the following treatment regimens: group
) 300 mg clopidogrel; group B) 600 mg clopidogrel; group
) 300 mg clopidogrel eptifibatide; and group D) 600 mg
lopidogrel  eptifibatide. The clopidogrel loading dose
as given to all patients immediately after stenting and was
ollowed by 75 mg daily. All patients had received at least 81
g aspirin for 7 days before the procedure and 325 mg was
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December 5, 2006:2186–91 Clopidogrel, GP IIb/IIIa Blocker, and Inflammationdministered on the day of the procedure and daily thereafter.
ptifibatide was administered as a double bolus (180 g/kg)
ollowed by an infusion (2 g/kg/min) for 18 to 24 h after the
rocedure (3). Unfractionated heparin was administered in
he catheterization laboratory immediately before stenting.
lood sampling. Blood samples were collected into tubes
ontaining 3.8% trisodium citrate (Becton-Dickinson,
utherford, New Jersey) after discarding the first 2 to 3 ml
f free-flowing blood before clopidogrel, eptifibatide, and
eparin administration (baseline) and at 8 and 18 to 24 h
fter stenting. Blood samples for platelet analyses and inflam-
ation markers were collected at baseline and 18 to 24 h after
tenting. In patients treated with eptifibatide, the final sample
as drawn at the time of completion of the infusion.
latelet aggregation. Platelet aggregation was assessed in
latelet-rich plasma after stimulation with adenosine
iphosphate (ADP) (5 M and 20 M) using a Chronolog
umi-Aggregometer (Model 490-4D) with the AGGRO/
INK software package (Chronolog, Havertown, Pennsyl-
ania). Aggregation was expressed as the maximum percent-
ge change in light transmittance from baseline with
latelet-poor plasma as a reference as previously described (4).
he absolute change in platelet aggregation was defined as
re-treatment aggregation post-treatment aggregation (10).
low cytometry. Whole blood flow cytometry using
-color analysis (Immunocytometry Systems, Cytometry
ource Book, Becton-Dickinson) was performed with the
ollowing monoclonal antibodies after stimulation with
DP as described previously: PAC-1 (recognizes activated
P IIb/IIIa receptors), CD41a (recognizes total GP IIb/
IIa receptors), and CD62P (recognizes P-selectin) (4).
-selectin was expressed as percentage positive cells,
hereas activated GP IIb/IIIa was expressed as log mean
uorescence intensity.
nflammation markers. The blood samples collected for
mmunoassays were centrifuged at 1400 g for 10 min, and
lasma samples were stored at70°C in aliquots until batch
nalysis. Measurements of C-reactive protein (CRP) and
umor necrosis factor (TNF)- were performed by enzyme-
inked immunosorbent assays using commercially available
Abbreviations and Acronyms
ADP  adenosine diphosphate
CK  creatinine kinase
CLEAR PLATELETS  Clopidogrel Loading With
Eptifibatide to Arrest the
Reactivity of Platelets
CRP  C-reactive protein
ELISA  enzyme-linked
immunosorbent assay
GP IIb/IIIa  glycoprotein IIb/IIIa
MFI  mean fluorescence intensity
PCI  percutaneous coronary
intervention
TNF  tumor necrosis factorits (Bender MedSystems, San Bruno, California). iardiac markers. The peak levels of troponin I, creatinine
inase-MB (CK-MB), and myoglobin were determined
sing the Triage Cardiac Panel with a Triage Meter
Biosite, San Diego, California). This method is based on a
uorescence immunoassay for the quantitative determina-
ion of these cardiac markers. The upper limit of normal
alue for troponin I is 0.4 ng/ml and for myoglobin 107
g/ml. A myocardial infarction was defined as CK-MB
3 upper limits of normal.
tatistical analysis. Categorical variables were compared
y Fischer exact test. The Student t test was used to compare
he groups treated with clopidogrel alone versus clopidogrel 
ptifibatide. Analysis of variance was used to compare
ubgroups and quartiles (Statistica Software, Tulsa, Okla-
oma). Values were expressed as mean  SD, and p  0.05
as considered significant.
ample size calculation. We hypothesized that there
ould be 25% difference in the CRP levels at 18 to 24 h
fter stenting between patients treated with clopidogrel
lone and patients treated with clopidogrel and eptifibatide.
o achieve a 90% power with an  of 5%, approximately 57
atients were required in each group (Sigmastat 3.1, Point
ichmond, California).
ESULTS
emographics and procedural characteristics are presented
n Tables 1 and 2. One hundred twenty patients were
nrolled. All procedures were elective. Twenty-one patients
ere admitted with unstable angina. Four patients, 2 in each
roup, presented with non–ST-segment elevation myocar-
ial infarction 48 h before randomization. The remainder
f the patients had stable angina. There were no significant
ifferences between the 2 groups in patient or procedural
haracteristics except that the eptifibatide with clopidogrel
roup had a higher number of patients with prior percuta-
eous transluminal coronary angioplasty.
latelet aggregation. Platelet aggregation induced by 5
M and 20 M ADP was the same in all groups at baseline
Table 3). In the groups treated with clopidogrel alone, 600
g inhibited platelet aggregation more than 300 mg at 18
o 24 h as measured by 5 and 20 M ADP-induced
ggregation (35  20% vs. 45  27% relative inhibition [p
0.044] and 24  10% vs. 37  23% [p  0.004],
espectively) (Fig. 1A). Platelet inhibition was near maximal
fter treatment with eptifibatide irrespective of the clopi-
ogrel loading dose. Overall, in patients treated with epti-
batide, there was near maximal inhibition of ex vivo
latelet aggregation compared with patients treated with
lopidogrel alone (p  0.001) (Table 3, Fig. 2).
low cytometry. GP IIb/IIIa. Baseline ADP-stimulated ex-
ression of activated GP IIb/IIIa was lower in groups
reated with eptifibatide (p  0.01) and decreased signifi-
antly in all groups after stenting (Figs. 1A and 2). In
atients treated with clopidogrel alone, there was no further
nhibition with the higher loading dose. Overall, at 18 to
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arkedly greater in patients treated with eptifibatide com-
ared with patients treated with clopidogrel alone (Fig. 2).
here was no effect of an increased dose of clopidogrel in
atients treated with a GP IIb/IIIa blocker (Fig. 1).
-SELECTIN. ADP-stimulated P-selectin expression was
he same in all groups before treatment (Table 3). High-
ose clopidogrel alone produced greater inhibition of stim-
lated P-selectin than standard-dose clopidogrel alone (p 
.01) (Fig. 1A). The addition of eptifibatide did not
roduce further inhibition of stimulated P-selectin (p 
.095) (Fig. 2). Moreover, less inhibition of P-selectin was
Table 1. Patient Demographics
Clopidogr
(n  60)
Age (yrs) 63  14
Race (Caucasian), n (%) 42 (70)
Gender (male), n (%) 38 (63)
BMI 29  5
Risk factors (%)
Smoking 45
Family history of CAD 38
Hypertension 60
Hyperlipidemia 80
Diabetes 50
Prior myocardial infarction 25
Prior CABG 25
Prior PTCA 35
Baseline medications (%)
Beta-blockers 87
ACE inhibitors 62
Calcium blockers 20
Lipid-lowering agents
CYP3A4 metabolized 62
Non-CYP3A4 metabolized 20
ACE  angiotensin-converting enzyme; BMI  body mass
artery disease; CYP  cytochrome P450; PTCA  percutan
Table 2. Procedural Characteristics
Clopidog
(n  60
Length of procedure (min) 60  2
Ejection fraction (%) 54  8
Number of vessels treated 1.2  0
Lesion morphology
De novo (%) 93
Lesion location (%)
Left anterior descending artery 32
Circumflex artery 23
Right coronary artery 40
Saphenous vein graft 5
Stent types (%)
Drug-eluting 70
Bare-metal 23
PTCA only 7
Reference vessel diameter (mm) 3.1  0
Total lesion length (mm) 20.2  1
Pre-stenosis (%) 85  7
Post-stenosis (%) 3  1PTCA  percutaneous transluminal coronary angioplasty.bserved in patients treated with 300 mg clopidogrel 
ptifibatide compared with 300 mg clopidogrel alone (p 
.001) (Fig. 1A).
nflammation markers. TNF-. Patients treated with 600
g clopidogrel had higher baseline TNF- levels (p 
.001) (Table 3). The TNF- levels decreased after 600 mg
lopidogrel treatment alone, whereas after 300 mg clopi-
ogrel treatment alone TNF- levels rose (p  0.001
ompared with 600 mg clopidogrel alone) (Fig. 1B). The
ddition of eptifibatide to 600 mg clopidogrel produced a
urther reduction in TNF- (p  0.001 compared with 600
g clopidogrel alone). Moreover, high-dose clopidogrel 
Clopidogrel  Eptifibatide
(n  60) p Value
65  12 0.40
42 (70) 1.00
42 (70) 0.41
30  6 0.32
38 0.43
36 0.82
73 0.13
87 0.30
53 0.74
35 0.23
20 0.51
55 0.03
97 0.05
75 0.36
27 0.13
57 0.57
20 1.0
; CABG  coronary artery bypass graft; CAD  coronary
transluminal coronary angioplasty.
Clopidogrel  Eptifibatide
(n  60) p Value
60  22 1.00
52  9 0.20
1.4  0.6 0.05
87 0.27
33 0.90
28 0.53
32 0.36
7 0.64
67 0.72
27 0.61
6 0.82
3.0  0.4 0.22
21  13.0 0.69
84  7 0.88
4  2 0.17elrel
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December 5, 2006:2186–91 Clopidogrel, GP IIb/IIIa Blocker, and Inflammationptifibatide was associated with greater inhibition of TNF-
release than standard-dose clopidogrel  eptifibatide
p  0.0097) (Fig. 1B). Overall, the addition of eptifibatide
roduced a significant change in TNF- compared with
lopidogrel therapy alone (7  16% vs. 32  14%; p 
.001) (Fig. 2).
RP. Baseline CRP levels did not differ between groups
Table 3). In patients treated with either 300 mg or 600 mg
lopidogrel alone, post-PCI CRP levels increased compared
ith baseline (p  0.001) and there was no difference
etween groups treated with 300 mg and 600 mg clopi-
able 3. Baseline Laboratory Measurements in Treatment Group
Clopidogrel
300 mg
(n  30)
Clopidogrel
600 mg
(n  30)
Clopid
Alo
(n 
TA, 5 M ADP (%) 60  9 62  16 61 
TA, 20 M ADP (%) 75  7 77  9 76 
P IIb/IIIa receptor, MFI
(stimulated)
138  35 141  11 140 
-selectin, % positive cells
(stimulated)
42  22 41  21 41 
NF- (pg/ml) 78  13 93  14 87 
RP (mg/l) 3.7  1.4 3.3  1.5 3.5 
p  0.01 clopidogrel alone versus clopidogrel  eptifibatide.
ADP  adenosine diphosphate; CRP  C-reactive protein; GP  glycoprotein;
umor necrosis factor.
igure 1. (A)Relative percentage change in adenosine diphosphate (ADP)–
nduced (5 and 20 M) platelet aggregation (LTA), P-selectin, and
ctivated glycoprotein (GP) IIb/IIIa expression in 4 treatment groups. The
values compare groups treated with 300-mg versus 600-mg clopidogrel
oses. (B) Relative percentage change in plasma tumor necrosis factor
TNF)- and C-reactive protein (CRP) levels in 4 treatment groups. The
values compare groups treated with 300-mg versus 600-mg clopidogrel
oses.
(
iogrel alone (Fig. 1B). Eptifibatide therapy significantly
educed CRP levels (p  0.001), and this effect was not
ependent on clopidogrel dose (Figs. 1B and 2).
yocardial necrosis markers. Overall CK-MB release
as significantly lower in the groups treated with eptifi-
atide (p  0.03) (Table 4). There were no infarcts in the
roup that received eptifibatide. Both myoglobin and tro-
onin I release were also higher in the groups treated with
lopidogrel alone (p  0.007 and p  0.07, respectively)
Table 4).
elation of inflammation markers, CK-MB release, and
latelet inhibition. Figure 3 demonstrates that patients
ith post-stenting myocardial infarction have significantly
igher CRP and TNF- release than patients without
ost-stenting infarction.
Figure 4A demonstrates that CRP release is related to the
egree of platelet inhibition. Patients with the greatest CRP
elease had less platelet inhibition than patients with the
east CRP release (p 0.003). The majority of patients with
he lowest quartile of CRP levels received eptifibatide (p 
.0012) (Fig. 4B). These data demonstrate that the use of
ptifibatide produces the greatest platelet inhibition which
s accompanied by the lowest degree of periprocedural
nflammation and myocardial necrosis.
Clopidogrel 
Eptifibatide
(n  60)
Clopidogrel 300 mg
 Eptifibatide
(n  30)
Clopidogrel 600 mg
 Eptifibatide
(n  30)
61  9 60  10 61  9
75  12 74  15 76  8
126  14* 121  8 128  17
37  12 36  10 39  14
84  15 85  15 83  11
3.6  1.5 3.8  1.3 3.2  1.4
 light transmittance aggregometry; MFI  mean fluorescence intensity; TNF 
igure 2. Relative percentage change in 5 and 20 M ADP–induced
latelet aggregation, activated GP IIb/IIIa receptor, P-selectin expression,
lasma TNF-, and CRP levels in patients treated with clopidogrel alones
ogrel
ne
60)
12
9
26
20
22
1.5open bars) and clopidogrel with eptifibatide (solid bars). Abbreviations as
n Figure 1.
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Clopidogrel, GP IIb/IIIa Blocker, and Inflammation December 5, 2006:2186–91ISCUSSION
he present study demonstrates that adjunctive therapy
ith a potent GP IIb/IIIa antagonist, eptifibatide, is asso-
iated with inhibition of inflammation and myocardial
ecrosis marker release in elective PCI. In patients treated
ith either 300 mg or 600 mg clopidogrel alone, CRP levels
ose early after stenting and TNF- rose after a 300 mg
lopidogrel load. Our findings suggest that GP IIb/IIIa
ntagonists may have extended benefits when added to
lopidogrel therapy in attenuating the inflammatory re-
ponse and myocardial necrosis marker release that follows
tent implantation.
Percutaneous coronary intervention induces inflamma-
ory responses through increased surface expression of
latelet-bound P-selectin and CD40L and subsequent for-
Table 4. Myocardial Necrosis Markers
Clopidogr
(n  60)
CK-MB (1–3  ULN), n (%) 11 (18%)
CK-MB (3  ULN), n (%) 5 (8%)
Tn-I (ULN), n (%) 9 (15%)
Myoglobin (2  ULN), n (%) 16 (27%)
CK-MB  creatinine kinase-MB; Tn-I  troponin I; ULN
igure 3. (A) Relation of maximum creatinine kinase-MB (CK-MB) to
ost-treatment plasma CRP (mg/l) levels. (B) Relation of necrosis marker
elease to post-treatment plasma TNF- (ng/ml) levels. NL  normal
imit; ULN  upper limit of normal; other abbreviations as in Figure 1.
q
qation of platelet-leukocyte aggregation, leading to vessel
all infiltration and inflammation marker release. In this
etting platelet activation is accompanied by pre-existing
ysfunctional endothelium that further affects the inflam-
atory response, as indicated by elevated systemic CRP
evels (11). Periprocedural adverse events may be related to
he magnitude of these platelet-related events and the
nflammatory response (6). Therefore, effective and maximal
eriprocedural inhibition of platelets may have the added
enefit of reducing inflammatory responses.
In the present study there was significant decrease in platelet
ggregation following treatment with a 600 mg clopidogrel
oading dose alone compared with the standard dose of 300
g. Adjunctive therapy with a GP IIb/IIIa inhibitor resulted
n near complete inhibition of platelet aggregation. Although
P IIb/IIIa inhibitors block platelet aggregation they do not
Clopidogrel  Eptifibatide
(n  60) p Value
3 (5%) 0.03
0 0.03
3 (5%) 0.07
4 (7%) 0.004
per limit of normal.
igure 4. (A) Observed frequency of absolute change in platelet aggregation
n each quartile of plasma C-reactive protein (CRP) levels. The p value
ompares platelet inhibition in patients with the lowest and highest quartiles
or CRP. (B) Observed frequency of patients treated with eptifibatide in eacheluartile of plasma CRP levels. The p values indicate the relation of each
uartile to the lowest quartile.
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December 5, 2006:2186–91 Clopidogrel, GP IIb/IIIa Blocker, and Inflammationave measurable effects on platelet adhesion and granular
ecretion (12). Likewise, in the present study the addition of a
P IIb/IIIa inhibitor did not provide any further inhibition of
-selectin expression compared with clopidogrel alone.
Clopidogrel is effective in inhibiting expression and
elease of inflammatory modulators from platelets, such as
-selectin and CD40L, and in inhibiting platelet-leukocyte
ggregate formation (5,6). Recently Vivekananthan et al. (7)
eported a decrease in CRP levels with clopidogrel pre-
reatment in patients undergoing PCI. However, in this
etrospective study up to 90% of patients also received
arious GP IIb/IIIa inhibitors and the timing was not
re-specified. In the present study, the timing of clopidogrel
nd GP IIb/IIIa blocker treatment was pre-specified. Al-
hough superior inhibition of platelet aggregation with
igh-dose clopidogrel alone was observed compared with
tandard-dose clopidogrel, only TNF- levels decreased,
hereas CRP levels rose after a high clopidogrel dose.
herefore, antiplatelet therapy with clopidogrel alone, irre-
pective of the dose, was not sufficient to overcome the
nflammatory response as indicated by CRP early after PCI.
ur data suggest that in the absence of eptifibatide TNF-
elease is dependent on clopidogrel dosing.
Varying effects of GP IIb/IIIa inhibitors on the release of
nflammatory markers have been reported after PCI (8,9).
he present study is the largest prospective comparative
nvestigation involving PCI patients where the effects of
ifferent doses of clopidogrel were studied with and without
GP IIb/IIIa blocker. In the present study the decrease in
he inflammatory response by GP IIb/IIIa blockade was
ccompanied by maximum inhibition of platelet aggregation
nd GP IIb/IIIa receptor expression but not P-selectin
xpression. Our data suggest that the decrease in the
nflammatory response may be independent of P-selectin
xpression. Previously, GP IIb/IIIa blockade has been
hown to improve endothelial function, reduce platelet
uperoxide release, and enhance platelet nitric oxide release
y inhibiting “outside-in” signaling (13,14). Therefore, the
et effect of inhibition of platelet function by clopidogrel,
hich blocks P2Y12-dependent “inside-out” signaling path-
ays and by GP IIb/IIIa blockers which inhibit “outside-in”
ignaling pathways, is a significant decrease in myocardial
ecrosis and the inflammatory response. Considering these
esults with those of the earlier CLEAR PLATELETS
tudy, maximum and early inhibition of platelet aggregation
rovides protection against myonecrosis and inflammation
ithin 24 h of stenting. These observations may provide a
echanistic explanation for the additional beneficial effects
f GP IIb/IIIa inhibitors on the development of short-term
dverse events after stenting.
tudy limitations. Stimulation of the inflammation re-
ponse by platelets includes expression and release of
D40L and platelet-leukocyte aggregate formation. In the
resent study both of these parameters were not studied.onclusions. A strategy of clopidogrel and eptifibatide sig-
ificantly inhibited the release of inflammatory and myocardial
ecrosis markers after elective stenting compared with clopi-
ogrel therapy alone. Inhibition of platelet aggregation and
ctive GP IIb/IIIa expression but not P-selectin expression was
ssociated with inhibition of inflammation. The mechanistic
nd clinical implications of attenuated periprocedural inflam-
ation and myocardial necrosis with a strategy of GP IIb/IIIa
nhibition warrant further investigation.
eprint requests and correspondence: Dr. Paul A. Gurbel, Sinai
enter for Thrombosis Research, Hoffberger Building, Suite 56,
401 W. Belvedere Avenue, Baltimore, Maryland 21215. E-mail:
gurbel@lifebridgehealth.org.
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